Global Medical Cannabis Market Segmentation, By Product (Oil, Medical Cannabis Capsules, Patch, Whole Flower, Ground Flower, Vape Pen, Dried Medical Cannabis, Creams & Moisturizer, Masks & Serum, Cleanser, and Others), Source (Natural and Synthetic), Species (Cannabis Indica, Sativa, and Hybrid), Application (Alzheimer’s Disease, Appetite Loss, Cancer, Inflammatory Bowel Diseases, Eating Disorders, Epilepsy, Autism, Mental Health Conditions, Multiple Sclerosis, Pain Management, Nausea, Muscle Spasms, Wasting Syndrome (Cachexia), Elevate Mood, Depression and Sleep Disorders, Anxiety, and Others), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC)/ Delta-8-Tetrahydrocannabinol, Cannabinol (CBN), Cannabicyclol (CBL), Cannabichromene (CBC), Cannabigerol (CBG), and Others), Treatment Type (Expectorant, Antiviral, Analgesic, Aphrodisiac, Psychedelic, and Others), Route of Administration (Oral Solutions and Capsules, Smoking, Vaporizers, Topicals, and Others), End User (Pharmaceutical Industry, Research and Development Centers, Homecare Setting, Hospital, Rehab Centers, and Others), Distribution Channel (B2B and B2C) – Industry Trends and Forecast to 2031
Medical Cannabis Market Analysis
The medical cannabis market has experienced significant growth in recent years, driven by increasing recognition of its therapeutic benefits for various medical conditions. With legalization efforts gaining momentum across multiple regions, the demand for medical cannabis products is on the rise. This market encompasses a wide range of products, including oils, capsules, and edibles, tailored for conditions such as chronic pain, epilepsy, and mental health disorders. Recent developments, such as advancements in cultivation techniques and extraction processes, have improved product quality and efficacy, further fueling market expansion. In addition, growing consumer awareness and acceptance, coupled with supportive government policies, are key factors contributing to the market's positive outlook. As research continues to unveil the potential benefits of cannabis, the medical cannabis market is poised for sustained growth, offering new opportunities for pharmaceutical companies and healthcare providers alike.
Medical Cannabis Market Size
The global medical cannabis market size was valued at USD 21.06 billion in 2023 and is projected to reach USD 108.90 billion by 2031, with a CAGR of 22.80% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Medical Cannabis Market Trends
“Demand for Personalized Cannabis Products”
The medical cannabis market is witnessing transformative trends driven by innovation and evolving consumer preferences. A notable trend is the growing demand for personalized cannabis products, where consumers seek tailored formulations to address specific health conditions and individual needs. Innovations in cannabis extraction and formulation techniques are enabling the development of diverse product offerings, such as targeted oils and infused edibles, that enhance therapeutic effects. In addition, advancements in technology, including the use of artificial intelligence and data analytics in cultivation and supply chain management, are optimizing production processes and ensuring product consistency. Overall, these trends reflect a shift towards more effective, customized medical cannabis solutions, catering to the diverse needs of patients and driving market growth.
Report Scope and Medical Cannabis Market Segmentation
|
Attributes
|
Medical Cannabis Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
MediPharm Labs Inc. (Canada), Tilray (Canada), Aurora Cannabis (Canada), JAZZ Pharmaceuticals Inc. (U.K.) (GW Pharmaceuticals plc), HEXO Corp. (Canada) (Zenabis Global Ltd), Cresco Labs (U.S.), Peace Naturals Project Inc. (Canada), CANOPY GROWTH CORPORATION (Canada), Medical Marijuana, Inc. (U.S.), Seed Cellar (U.S.), EcoGen Biosciences (U.S.), CANNABIS SEEDS USA (U.S.), Seeds For Me (U.S.), HUMBOLDT SEED COMPANY (U.S.), Extractas (U.S.), World Class Cannabis Seeds (Crop King Seeds) (Canada), BARNEY'S FARM (Netherlands), FOLIUM BIOSCIENCES (U.S.), PharmaHemp (U.K.), Elixinol Global Limited (Australia), ENDOCA (Netherlands), Harmony (U.K.), MARY’S Nutritionals, LLC (U.S.), Pure Ratios (U.S.), Greenwich Biosciences, Inc. (U.S.), Upstate Elevator Supply Co. (U.S.), Apothecanna (U.S.), BOL Pharma (Israel), IDT Australia (Australia)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Medical Cannabis Market Definition
Medical cannabis refers to the use of the cannabis plant and its derivatives for therapeutic purposes. It encompasses a variety of products, including oils, capsules, tinctures, and topical formulations, containing cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Medical cannabis is prescribed to alleviate symptoms associated with various health conditions, including chronic pain, epilepsy, multiple sclerosis, nausea from chemotherapy, and anxiety. Its use is often regulated by laws that vary by region, and it is typically recommended when conventional treatments have proven ineffective.
Medical Cannabis Market Dynamics
Drivers
- Increasing Acceptance and Legalization
The increasing acceptance of medical cannabis among healthcare professionals and medical cannabis patients is a significant driver of market growth. As research continues to unveil the therapeutic benefits of cannabinoids for various medical conditions, healthcare providers are more inclined to recommend cannabis as a treatment option. This shift in perception has led to greater patient awareness and willingness to consider medical cannabis for managing chronic pain, anxiety, and other ailments. Moreover, the legalization of medical cannabis in numerous regions has further facilitated its integration into mainstream healthcare. This regulatory change legitimizes its use and encourages investment in research and product development, thus expanding the market. The combined effect of these factors is expected to foster significant growth in the medical cannabis market.
- Rising Prevalence of Chronic Diseases
The rising incidence of chronic diseases, including cancer, epilepsy, and multiple sclerosis, has created a substantial demand for effective pain management and therapeutic solutions, significantly boosting the medical cannabis market. Patients suffering from these conditions often experience severe pain, discomfort, and a range of debilitating symptoms that conventional treatments may not adequately address. Medical cannabis, with its diverse array of cannabinoids, offers a natural alternative that can alleviate pain and improve quality of life. As healthcare providers increasingly recognize the potential of cannabis-based treatments, more patients are being referred to medical cannabis as a viable option. This growing acceptance, alongside ongoing research demonstrating the efficacy of cannabis for symptom relief, continues to propel market growth as patients seek effective and holistic approaches to managing their health conditions.
Opportunities
- Integration with Traditional Healthcare
Collaborations between cannabis companies and traditional healthcare providers present a significant opportunity for market growth in the medical cannabis sector. By partnering with healthcare professionals, cannabis companies can enhance the legitimacy of their products and foster trust among potential patients. These collaborations can lead to the development of educational programs and clinical guidelines, making healthcare providers more comfortable recommending cannabis therapies as part of a comprehensive treatment plan. As healthcare providers gain confidence in the efficacy and safety of medical cannabis, they are more likely to advocate for its use, ultimately increasing patient access to these therapies. This integration broadens the market reach of cannabis products and contributes to the overall acceptance of medical cannabis within mainstream healthcare, driving sustained market expansion.
- Advancements in Research and Development
Ongoing research into the therapeutic benefits of cannabinoids is unlocking new opportunities in the medical cannabis market. As scientists and healthcare professionals continue to explore the medicinal properties of various cannabinoids, they are discovering innovative applications for conditions ranging from chronic pain and anxiety to neurological disorders. This research has led to the development of new medical cannabis products, expanding the variety of treatment options available to patients. Such advancements cater to diverse patient needs and enhance the efficacy and safety profiles of cannabis-based therapies. As more clinical studies validate the benefits of these products, they are likely to gain acceptance among healthcare providers and patients alike. This expansion of product offerings presents a lucrative opportunity for companies to capture a larger share of the growing medical cannabis market, ultimately improving patient outcomes and satisfaction.
Restraints/Challenges
- Lack of Standardized Regulations
The medical cannabis market faces significant challenges due to the lack of standardized regulations and the varying legal frameworks across different regions. Each jurisdiction has its own rules governing the cultivation, distribution, and sale of medical cannabis, creating a complex landscape for companies to navigate. This regulatory inconsistency often results in confusion and delays in market entry for new players. Companies may spend considerable time and resources understanding local laws, obtaining necessary licenses, and ensuring compliance with diverse regulations. These hurdles can deter potential investors and limit the growth of the market. Consequently, the absence of a unified regulatory approach poses a significant challenge to the expansion and accessibility of medical cannabis products globally.
- Competition from Traditional Therapies
Established pharmaceutical treatments continue to hold a significant share of the healthcare market, often backed by extensive research, clinical trials, and regulatory approvals. These conventional therapies are widely prescribed by healthcare professionals and have a long-standing reputation for safety and efficacy. As a result, patients and doctors may be hesitant to consider medical cannabis products as viable alternatives, especially in serious conditions like cancer and chronic pain. The familiarity and trust in traditional medications can hinder the adoption of medical cannabis, despite its potential benefits. This reliance on established treatments limits the market growth for cannabis-based therapies, as healthcare professionals may prioritize familiar pharmaceutical options over newer, less understood cannabis products. This restraint creates a challenge for the medical cannabis market to gain traction among patients and healthcare providers.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Medical Cannabis Market Scope
The market is segmented on the basis of product, source, species, derivatives, application, route of administration, treatment type, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Oil
- Medical Cannabis Capsules
- Patch
- Whole Flower
- Ground Flower
- Vape Pen
- Dried Medical Cannabis
- Creams & Moisturizers
- Masks & Serum
- Cleanser
- Others
Source
- Natural
- Synthetic
Species
- Cannabis Indica
- Cannabis Sativa
- Hybrid
Application
- Alzheimer’s Disease
- Appetite Loss
- Cancer
- Inflammatory Bowel Diseases
- Eating Disorders
- Epilepsy
- Autism
- Mental Health Conditions
- Multiple Sclerosis
- Pain Management
- Nausea
- Muscle Spasms
- Wasting Syndrome (Cachexia)
- Elevate Mood
- Depression and Sleep Disorders
- Anxiety
- Others
Derivatives
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC) / Delta-8-Tetrahydrocannabinol
- Cannabinol (CBN)
- Cannabicyclol (CBL)
- Cannabichromene (CBC)
- Cannabigerol (CBG)
- Others
Treatment Type
- Expectorant
- Antiviral
- Analgesic
- Aphrodisiac
- Psychedelic
- Others
Route of Administration
- Oral Solutions and Capsules
- Smoking
- Vaporizers
- Topicals
- Others
End User
- Pharmaceutical Industry
- Research and Development Centers
- Homecare Setting
- Hospitals
- Rehab Centers
- Others
Distribution Channel
- B2B
- B2C
Medical Cannabis Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, product, source, species, derivatives, application, route of administration, treatment type, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the global medical cannabis market due to the increasing investment in medical cannabis. The U.S. is expected to dominate the North America region due to the legalization of medical cannabis use. Germany is expected to dominate the Europe region due to the increasing demand for medical cannabis in emerging markets and expansion. Australia is expected to dominate the Asia-Pacific region due to the presence of key manufacturers and advanced technological processes.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Medical Cannabis Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Medical Cannabis Market Leaders Operating in the Market Are:
- MediPharm Labs Inc. (Canada)
- Tilray (Canada)
- Aurora Cannabis (Canada)
- JAZZ Pharmaceuticals Inc. (U.K.) (GW Pharmaceuticals plc)
- HEXO Corp. (Canada) (Zenabis Global Ltd)
- Cresco Labs (U.S.)
- Peace Naturals Project Inc. (Canada)
- CANOPY GROWTH CORPORATION (Canada)
- Medical Marijuana, Inc. (U.S.)
- Seed Cellar (U.S.)
- EcoGen Biosciences (U.S.)
- CANNABIS SEEDS USA (U.S.)
- Seeds For Me (U.S.)
- HUMBOLDT SEED COMPANY (U.S.)
- Extractas (U.S.)
- World Class Cannabis Seeds (Crop King Seeds) (Canada)
- BARNEY'S FARM (Netherlands)
- FOLIUM BIOSCIENCES (U.S.)
- PharmaHemp (U.K.)
- Elixinol Global Limited (Australia)
- ENDOCA (Netherlands)
- Harmony (U.K.)
- MARY’S Nutritionals, LLC (U.S.)
- Pure Ratios (U.S.)
- Greenwich Biosciences, Inc. (U.S.)
- Upstate Elevator Supply Co. (U.S.)
- Apothecanna (U.S.)
- BOL Pharma (Israel)
- IDT Australia (Australia)
Latest Developments in Medical Cannabis Market
- In February 2023, Aurora Cannabis Inc., a Canadian company specializing in global cannabis distribution, collaborated with MedReleaf Australia to launch CraftPlant, a new medical cannabis brand for the Australian market. The initial offerings from CraftPlant include three products—Greendae, Navana, and HiVolt—all of which are now available for prescription by doctors. Each strain boasts a high THC concentration and is sourced from premium cultivars developed by Occo, Aurora's leading scientific and genetics company, and will be packaged in 10g canisters produced under strict EU-GMP authorized standards
- In July 2023, Carer, an oncology company in India, announced a partnership with Wholeleaf, a certified manufacturer of medicinal cannabis and cannabidiol. This collaboration aims to improve the overall well-being of cancer patients by offering comprehensive support that includes nutrition for caregivers, physical therapy, and mental health services. With official approval from the Ayush ministry to manufacture and market its products nationwide, CARER and Wholeleaf are combining their services to deliver a holistic solution for cancer care
- In September 2023, Alternaleaf, a clinic recognized for helping Australians obtain medicinal cannabis, announced its expansion into the United Kingdom. Research indicates that England is on track to become the second-largest market for medicinal cannabis in Europe, driven by growing demand. With over 360,000 reported cases of opioid addiction in the UK, experts suggest that medicinal cannabis could serve as a viable alternative to opioids, which are frequently prescribed unnecessarily
- In April 2022, Medi Cane Health Inc. and Dr. Reddy's Laboratories Ltd. launched their medical cannabis product in Germany. This collaboration aims to meet the growing demand for medical cannabis solutions in the region. The introduction of this product marks a significant step in expanding access to therapeutic cannabis options for patients in Germany
- In April 2022, New York City witnessed its first legal marijuana sales, occurring just a month after seven medical marijuana businesses received approval to sell their products to all adults. This milestone signifies a significant shift in the state's cannabis landscape, expanding access beyond medicinal use. The initiative aims to create a regulated market while benefiting local economies and ensuring consumer safety
SKU-